NCT06169202

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

A Real-world Observational Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients With Advanced Colorectal Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: China Medical University, China · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer.

Detailed description

This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer..The purpose of the study is exploring the real-world efficacy and safety of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with metastatic colorectal adenocarcinoma.

Conditions

• Fruquintinib
• Irinotecan
• Capecitabine
• Gastrointestinal Tumours

Interventions

Type	Name	Description
DEVICE	fruquintinib	4 mg orally once daily, D1-14, repeated every 3 weeks.
DRUG	Irinotecan	180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
DRUG	Capecitabine	1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.

Timeline

• Start date: 2023-06-01
• Primary completion: 2025-04-01
• Completion: 2025-06-01
• First posted: 2023-12-13
• Last updated: 2023-12-13

Locations

1 site across 1 country: China